November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
November, 2024 Cambridge, MA – Portal Instruments is pleased to announce that Steven Kaufman will be joining Portal Instruments as their interim Chief Commercial Officer.
Steven is a recognized leader in the device industry, having held numerous leadership roles related to Business Development, Product Management, Marketing and Strategy. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
Patrick Anquetil, CEO, welcomed Steven, noting Steven's broad expertise in the area of self-injection devices and his proven track-record taking devices from design, development, manufacture, final assembly to clinical and then commercial launch in Europe, North America and APAC. "Steven's expertise in drug delivery will be a strong asset to Portal Instruments as we continue to move towards commercialization."
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
August 29, 2024 - Patrick Anquetil talks with Ryan Cote on the Manufacturer's Mindset Podcast. They discuss insights, challenges, and the lessons learned on the journey of revolutionizing needle-free injections at Portal Instruments.
November 21, 2023 - Patrick Anquetil, CEO of Portal Instruments, takes the stage at LSI's 2023 Emerging MedTech Summit in Dana Point, California. Tune in to the recorded session to hear Dr. Anquetil dive into the innovative world of of needle-free and Portal's groundbreaking needle-free technology.
Please fill out the details below and we will get back to you shortly.